

## Übersicht Publikationen

Prof. Dr. med. Christoph Thomssen für die Jahre 2011 und 2012

### Journalbeitrag

1. Blohmer J, Paepke S, Sehouli J, Blohmer D, Kolben M, Würschmidt F, Petry KU, Kimmig R, Elling D, Thomssen C, von Minckwitz G, Möbus V, Hinke A, Kümmel S, Budach V, Lichtenegger W, Schmid P (2011) Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study. *J CLIN ONCOL*, 29(28): 3791-3792
2. Gnant M, Harbeck N, Thomssen C (2011) St. Gallen 2011: Summary of the Consensus Discussion. *BREAST CARE*, 6(2): 136-141
3. Guo X, Loibl S, Untch M, Möbus V, Schwedler K, Fasching PA, Barinoff J, Holms F, Thomssen C, Zahm DM, Kreienberg R, Hauschild M, Eidtmann H, Tauchert S, Mehta K, von Minckwitz G (2011) Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy. *BREAST CARE*, 6(4): 279-283
4. Harbeck N, Thomssen C (2011) A new look at node-negative breast cancer. *ONCOLOGIST*, 16: 51-60
5. Huober J, Paepke PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, Kubista E, Baumgärtner AK, Beckmann MW, May C, Nimmrich I, Harbeck N (2011) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial. *BREAST*, 19: 1-11
6. Kantelhardt EJ, Vetter M, Schmidt M, Veyret C, Augustin D, Hanf V, Meisner C, Paepke D, Schmitt M, Sweep F, von Minckwitz G, Martin PM, Jaenicke F, Thomssen C, Harbeck N (2011) Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6xFEC versus 3xFEC/3xDocetaxel. *BMC CANCER*, 11: 140
7. Pivot X, Schneeweiss A, Verma S, Thomssen C, Passos-Coelho JL, Benedetti G, Ciruelos E, von Moos R, Chang HT, Duenne AA, Miles DW (2011) Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: results from AVADO. *EUR J CANCER*, 47(16): 1387-2395
8. Schmitt M, Harbeck N, Brünner N, Jänicke F, Meisner C, Mühlenweg B, Jansen H, Dorn J, Nitz U, Kantelhardt EJ, Thomssen C (2011) Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. *EXPERT REV MOL DIAGN*, 11: 617-34
9. Smith IE, Pierga JY, Biganzoli L, Cortés-Funes H, Thomssen C, Pivot X, Fabi A, Xu B, Stroyakovskiy D, Franke FA, Kaufman B, Mainwaring P, Pienkowski T, De Valk B, Kwong A, González-Trujillo JL, Koza I, Petrakova K, Pereira D, Pritchard KI (2011) First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. *ANN ONCOL*, 22: 595-602
10. Smith I, Pierga JY, Biganzoli L, Cortes-funes H, Thomssen C, Saracchini S, Nisenbaum B, Peleaz I, Duenne AA, Pritchard K (2011) Final overall survival results and effect of prolonged (? 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. *Breast Cancer Res Treat*, 130(1): 133-143
11. Stang A, Trocci P, Ruschke K, Schmidt-Pokrzywniak A, Holzhausen J, Löning T, Buchmann J, Thomssen C, Lantzsch T, Hauptmann S, Böcker W, Kluttig A (2011) Factors influencing the agreement on histopathological assessments of breast biopsies among pathologists. *HISTOPATHOLOGY*, 59(5): 939-49
12. Thomssen C, Scharl A, Harbeck N (2011) AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. *BREAST CARE*, 6 (4): 299-313
13. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). *BREAST*, 21: 242-52

14. Dämmrich M, Thomssen C, Hillemanns P, Kreipe H (2012) [Intraoperative pathological rapid investigations in breast surgery]. *PATHOLOGE*, 33: 424-9
15. Huober J, Fasching PA, Barsoum M, Petruzelka L, Wallwiener D, Thomssen C, Reimer T, Paepke S, Azim HA, Ragosch V, Kubista E, Baumgärtner AK, Beckmann MW, May C, Nimmrich I, Harbeck N (2012) Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. *BREAST*, 21: 27-33
16. Surov A, Holzhausen HJ, Wienke A, Schmidt J, Thomssen C, Arnold D, Ruschke K, Spielmann RP (2012) Primary and secondary breast lymphoma: prevalence, clinical signs and radiological features. *BRIT J RADIOL*, 85: e195-205
17. Thomssen C (2012) [Is non-oral hormonal contraception really free of risks? Comment on the case report by Spinner et al]. *INTERNIST*, 53: 982-4
18. Thomssen C, Marschner N, Untch M, Decker T, Hegewisch-Becker S, Jackisch C, Janni W, Hans-Joachim L, von Minckwitz G, Scharl A, Schneeweiss A, Tesch H, Welt A, Harbeck N (2012) ABC1 Consensus Conference - a German Perspective: First International Consensus Conference on Advanced Breast Cancer (ABC1), Lisbon, November 5, 2011. *BREAST CARE*, 7: 52-59
19. Thomssen C, Pierga JY, Pritchard KI, Biganzoli L, Cortes-Funes H, Petráková K, Kaufman B, Duenne A, Smith I (2012) First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. *ONCOLOGY-BASEL*, 82: 218-27
20. Trocchi P, Ursin G, Kuss O, Ruschke K, Schmidt-Pokrzywniak A, Holzhausen HJ, Löning T, Thomssen C, Böcker W, Kluttig A, Stang A (2012) Mammographic density and inter-observer variability of pathologic evaluation of core biopsies among women with mammographic abnormalities. *BMC CANCER*, 12: 554
21. Wagner AD, Thomssen C, Haerting J, Unverzagt S (2012) Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. *COCHRANE DB SYST REV*, 7: CD008941
22. Wenners AS, Mehta K, Loibl S, Park H, Mueller B, Arnold N, Hamann S, Weimer J, Ataseven B, Darb-Esfahani S, Schem C, Mundhenke C, Khandan F, Thomssen C, Jonat W, Holzhausen HJ, von Minckwitz G, Denkert C, Bauer M (2012) Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. *PLOS ONE*, 7: e45826

### **Buchbeitrag**

1. Thomssen C (2011) Brustkrebs Patientenratgeber zu den AGO-Empfehlungen 2011. In: AGO Kommission Mamma (Hg.) Brustkrebs Patientenratgeber zu den AGO-Empfehlungen 2011. Zuckschwerdt München, München, 1-81
2. Untch M, Thomssen C, Costa SD (2011) Endokrine Therapie beim Mammakarzinom. In: Untch, Thomssen, Serban (Hg.) Colloquium Senologie. Agileum, München, 137-157